Global Anlotinib Hydrochloride Market Strategic Research Report

Scope of the Report

The global Anlotinib Hydrochloride market size is predicted to grow from US$ 540 million in 2025 to US$ 1,184 million in 2032; it is expected to grow at a CAGR of 9.8% from 2026 to 2032.

In 2025, global production of Anlotinib Hydrochloride reached approximately 12.5 million units.Anlotinib Hydrochloride is an oral small-molecule multi-target tyrosine kinase inhibitor (TKI) primarily used for the treatment of various solid tumors, including non-small cell lung cancer, soft tissue sarcoma, and thyroid cancer. It exerts its effects by simultaneously inhibiting multiple signaling pathways, such as vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFR), and platelet-derived growth factor receptors (PDGFR), thereby achieving anti-angiogenic activity and suppression of tumor growth. Anlotinib hydrochloride offers the convenience of oral administration, multi-target synergistic effects, and a certain degree of broad-spectrum antitumor activity, making it clinically valuable in the treatment of advanced cancers as well as in maintenance therapy.

Anlotinib Hydrochloride, as a multi-target tyrosine kinase inhibitor (TKI), holds an important position in China’s oncology targeted therapy market, particularly demonstrating strong competitiveness in indications such as non-small cell lung cancer and soft tissue sarcoma. With the continuous rise in cancer incidence and the increasing adoption of precision medicine, the market for small-molecule targeted therapies is steadily expanding, providing a stable demand foundation for this drug. From a competitive landscape perspective, multi-target TKIs represented by Sorafenib and Lenvatinib, along with emerging therapies such as immune checkpoint inhibitors, constitute the primary competitive environment. However, anlotinib hydrochloride, with its multi-target mechanism, broad indication coverage, and domestic pricing advantages, demonstrates differentiated competitiveness in later-line and maintenance therapy settings. On the policy side, its inclusion in the national reimbursement drug list helps improve patient accessibility and promote market expansion, although volume-based procurement and healthcare cost-control policies continue to exert downward pressure on pricing. From a competitive standpoint, the increasing availability of similar targeted therapies from both domestic and international players, combined with the rise of immunotherapy-based combination regimens, is intensifying market competition. Therefore, the future market performance of anlotinib hydrochloride will depend on its progress in combination strategies, expansion into additional indications (such as other solid tumors), and the accumulation of real-world evidence, as well as its overall competitive balance in efficacy, safety, and cost.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Anlotinib Hydrochloride market?

What factors are driving Anlotinib Hydrochloride market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Anlotinib Hydrochloride market opportunities vary by end market size?

How does Anlotinib Hydrochloride break out by Type, by Application?

This report presents a comprehensive overview of the global Anlotinib Hydrochloride market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 8 mg/capsule
• 12 mg/capsule

Segment by Dosage Form

• Capsule
• Tablet

Segment by Sales Channels

• Hospital
• Retail
• Online

Segment by Application

• Non-small Cell Lung Cancer（NSCLC）
• Small Cell Lung Cancer（SCLC）
• Soft Tissue Sarcoma（STS）
• Thyroid Cancer
• Hepatocellular Carcinoma（HCC）
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Anlotinib Hydrochloride market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Non-small Cell Lung Cancer（NSCLC）, Small Cell Lung Cancer（SCLC）, Soft Tissue Sarcoma（STS） evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact